Neurological Institute Outcomes
Brain Tumor Distributions
The Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (BBTC) of the Neurological Institute is one of the largest and most comprehensive programs in the country and is dedicated to providing exceptional patient care including surgery, radiation, chemotherapy, and clinical research trials for brain tumor patients. Patient care is provided by a multidisciplinary team consisting of neurosurgeons, radiation oncologists, neuro-oncologists, medical oncologists, psychiatrists, and neuropsychologists, along with nurses, physician assistants, case managers, and social workers who all specialize in treating patients with brain tumors. The department is dedicated to bringing novel treatment options emerging from the institute’s extensive basic and translational research programs. The primary mission is to offer excellent care through state-of-the-art surgical intervention and conducting clinical research to enhance patient outcomes. The BBTC enrolled 377 patients in therapeutic research trials in the past 5 years (2014–2018). In 2018, 114 patients with newly diagnosed glioblastoma, the most common type of malignant primary brain tumor, underwent their initial surgical resection at the BBTC. Approximately 12,000 cases of glioblastoma are diagnosed each year in the United States.
Brain Tumor Diagnosis Distribution (N = 2029)